Study aims and goal: A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 in Adults with Early Manifest Huntington’s Disease.
No. of study participants and sites: This open-label study aims to recruit participants from 2 sites in France.
For further information see the clinical trial registration.